Molecular Targets of Shenqi Dihuang, A Traditional Chinese Herbal Medicine, and Its Potential Role in Renal Cell Carcinoma Therapy. (25th January 2023)

• Record Type: Journal Article
• Authors: Chen, Xinglin; Zhang, Tongtong; Zhan, Xiangyang; Zang, Xinyue; Zhai, Xinyu; Wan, Zhong; Ge, Minyao; Tan, Mingyue; Gu, Jianyi; Xu, Dongliang
• Other Names: Liu Hongda Academic Editor.
• Is Part Of: Genetical research. Volume 2023(2023)
• Publication Date: 2023-01-25
• Subjects: Genetics -- Periodicals; Heredity -- Periodicals; 576.5
• DOI: 10.1155/2023/2355891
• Languages: English
• ISSNs: 0016-6723

Abstract

Abstract : Chinese herbal medicine (CHM), which includes herbal slices and proprietary products, is widely used in China. Shenqi Dihuang (SQDH) is a traditional Chinese medicine (TCM) formula with ingredients that affect tumor growth. Despite recent advances in prognosis, patients with renal cell carcinoma (RCC) cannot currently receive curative treatment. The present study aimed to explore the potential target genes closely associated with SQDH. The gene expression data for SQDH and RCC were obtained from the TCMSP and TCGA databases. The SQDH-based prognostic prediction model reveals a strong correlation between RCC and SQDH. In addition, the immune cell infiltration analysis indicated that SQDH might be associated with the immune response of RCC patients. Based on this, we successfully built the prognostic prediction model using SQDH-related genes. The results demonstrated that CCND1 and NR3C2 are closely associated with the prognosis of RCC patients. Finally, the pathways enrichment analysis revealed that response to oxidative stress, cyclin binding, programmed cell death, and immune response are the most enriched pathways in CCND1. Furthermore, transcription regulator activity, regulation of cell population proliferation, and cyclin binding are closely associated with the NR3C2.